{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T01:51:20Z","timestamp":1772589080142,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet Neurology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/s1474-4422(13)70014-0","type":"journal-article","created":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T23:15:34Z","timestamp":1359587734000},"page":"233-243","source":"Crossref","is-referenced-by-count":156,"title":["Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial"],"prefix":"10.1016","volume":"12","author":[{"given":"Richard","family":"Dodel","sequence":"first","affiliation":[]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"F\u00f6rster","sequence":"additional","affiliation":[]},{"given":"Yaroslav","family":"Winter","sequence":"additional","affiliation":[]},{"given":"Jan-Philipp","family":"Bach","sequence":"additional","affiliation":[]},{"given":"Julius","family":"Popp","sequence":"additional","affiliation":[]},{"given":"Judith","family":"Alferink","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[]},{"given":"Katharina","family":"Buerger","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[]},{"given":"Piero","family":"Antuono","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Jacoby","sequence":"additional","affiliation":[]},{"given":"Ralph","family":"Richter","sequence":"additional","affiliation":[]},{"given":"James","family":"Stevens","sequence":"additional","affiliation":[]},{"given":"Isaac","family":"Melamed","sequence":"additional","affiliation":[]},{"given":"Jerome","family":"Goldstein","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"Haag","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"Wietek","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Farlow","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1474-4422(13)70014-0_bib1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer's disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/S1474-4422(13)70014-0_bib2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","article-title":"Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease","volume":"75","author":"Dodel","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S1474-4422(13)70014-0_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1212\/WNL.57.5.801","article-title":"Reduced levels of amyloid beta-peptide antibody in Alzheimer disease","volume":"57","author":"Du","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(13)70014-0_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S1092852900027061","article-title":"Current state of immunotherapy for Alzheimer's disease","volume":"13","author":"Relkin","year":"2008","journal-title":"CNS Spectr"},{"key":"10.1016\/S1474-4422(13)70014-0_bib5","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","volume":"30","author":"Relkin","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.1016\/S1474-4422(13)70014-0_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug insight: the use of intravenous immunoglobulin in neurology\u2013therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/S1474-4422(13)70014-0_bib7","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","article-title":"Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals","volume":"37","author":"Weksler","year":"2002","journal-title":"Exp Gerontol"},{"key":"10.1016\/S1474-4422(13)70014-0_bib8","first-page":"449","article-title":"IVIG therapy of mild to moderate Alzheimer's disease patients showed significant benefits as measured by neuroimaging and neuropsychological testing in a phase II, randomized, double blind placebo controlled clinical study","volume":"50","author":"Weksler","year":"2010","journal-title":"Gerontologist"},{"issue":"suppl 4","key":"10.1016\/S1474-4422(13)70014-0_bib9","doi-asserted-by":"crossref","first-page":"P589","DOI":"10.1016\/j.jalz.2012.05.1606","article-title":"Three-year follow-up on the IVIG for Alzheimer's phase II study","volume":"8","author":"Relkin","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/S1474-4422(13)70014-0_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(13)70014-0_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/S1474-4422(13)70014-0_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: a preliminary report","volume":"17","author":"Yesavage","year":"1983","journal-title":"J Psychiatr Res"},{"key":"10.1016\/S1474-4422(13)70014-0_bib13","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","article-title":"Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease","volume":"295","author":"DeMattos","year":"2002","journal-title":"Science"},{"key":"10.1016\/S1474-4422(13)70014-0_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12603-009-0059-0","article-title":"Evolution of Abeta42 and Abeta40 levels and Abeta42\/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment","volume":"13","author":"Blennow","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/S1474-4422(13)70014-0_bib15","series-title":"Pharmacokinetic & pharmacodynamic data analysis. Concepts and applications","author":"Gabrielsson","year":"2007"},{"key":"10.1016\/S1474-4422(13)70014-0_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2796.2010.02315.x","article-title":"Immunotherapy for Alzheimer's disease","volume":"269","author":"Morgan","year":"2011","journal-title":"J Intern Med"},{"key":"10.1016\/S1474-4422(13)70014-0_bib17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","article-title":"Can Alzheimer disease be prevented by amyloid-beta immunotherapy?","volume":"6","author":"Lemere","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/S1474-4422(13)70014-0_bib18","first-page":"797","article-title":"Bapineuzumab IV phase 3 results","volume":"16","author":"Scheltens","year":"2012","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/S1474-4422(13)70014-0_bib19","first-page":"801","article-title":"Safety and efficacy of solanezumab in patients with mild to moderate Alzheimer's disease: results from phase 3","volume":"16","author":"Doody","year":"2012","journal-title":"J Nutr Health Aging"},{"issue":"suppl","key":"10.1016\/S1474-4422(13)70014-0_bib20","doi-asserted-by":"crossref","first-page":"P456","DOI":"10.1016\/j.jalz.2012.05.1216","article-title":"The Gammaglobulin Alzheimer Partnership Study (GAP): design, screening, enrollment and futility analysis results","volume":"8","author":"Relkin","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/S1474-4422(13)70014-0_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/S1474-4422(13)70014-0_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1212\/WNL.0b013e3182661f91","article-title":"Microbleeds do not affect rate of cognitive decline in Alzheimer disease","volume":"79","author":"van der Vlies","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/S1474-4422(13)70014-0_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"issue":"suppl 5","key":"10.1016\/S1474-4422(13)70014-0_bib24","doi-asserted-by":"crossref","first-page":"V75","DOI":"10.1007\/s00415-006-5013-z","article-title":"Adverse effects of treatment with intravenous immunoglobulins for neurological diseases","volume":"253","author":"Wittstock","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/S1474-4422(13)70014-0_bib25","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/S1474-4422(13)70014-0_bib26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1515\/CCLM.2010.131","article-title":"Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall","volume":"48","author":"Mattsson","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/S1474-4422(13)70014-0_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/bmm.12.51","article-title":"Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease","volume":"6","author":"Herholz","year":"2012","journal-title":"Biomark Med"},{"key":"10.1016\/S1474-4422(13)70014-0_bib28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.neuroimage.2010.02.064","article-title":"Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative","volume":"51","author":"Chen","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/S1474-4422(13)70014-0_bib29","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/JGP.0b013e3181faec23","article-title":"Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study","volume":"19","author":"Tschanz","year":"2011","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/S1474-4422(13)70014-0_bib30","article-title":"Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores","author":"Williams","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/S1474-4422(13)70014-0_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1017\/S1041610200006359","article-title":"Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis","volume":"12","author":"Han","year":"2000","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/S1474-4422(13)70014-0_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jalz.2010.03.018","article-title":"Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database","volume":"7","author":"Ito","year":"2011","journal-title":"Alzheimers Dement"}],"container-title":["The Lancet Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1474442213700140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1474442213700140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T22:57:05Z","timestamp":1539903425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1474442213700140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1474442213700140"],"URL":"https:\/\/doi.org\/10.1016\/s1474-4422(13)70014-0","relation":{},"ISSN":["1474-4422"],"issn-type":[{"value":"1474-4422","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}